ArticleThe Journal of experimental medicine2021
ILC3s control splenic cDC homeostasis via lymphotoxin signaling.
Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Spatial and functional specialization of human splenic innate lymphoid cells.Nature communications · 2026Article
- B cells maintain the homeostasis of splenic marginal zone antigen-presenting cells to promote the antiviral CD8Cellular & molecular immunology · 2026Article
- Dendritic Cell Organization and Function in Innate and Adaptive Immune Defense Within Lymph Nodes.Immunological reviews · 2026Review
- Sequential lymphotoxin-β receptor and retinoic acid receptor signals regulate cDC2 fate.Nature immunology · 2025Article
- TLR ligand sensing by lymph node FRCs directs intranodal lymphocyte accumulation to promote immune responses.iScience · 2025Article
- Ontogenetic Diversification of Type 2 Conventional Dendritic Cells in the Bone Marrow: A Central Logic for Peripheral Immunity.Immunological reviews · 2025Review
- Sequential Lymphotoxin Beta Receptor and Retinoic Acid Receptor signals regulate cDC2 fates.Research square · 2025Article
- B cells are not drivers of stromal cell activation during acute CNS infection.Journal of neuroinflammation · 2025Article
- Distinct ontogenetic lineages dictate cDC2 heterogeneity.Nature immunology · 2024Article
- Antibiotic-mediated dysbiosis leads to activation of inflammatory pathways.Frontiers in immunology · 2024Article
- Lymphocyte homing and recirculation with tumor tertiary lymphoid structure formation: predictions for successful cancer immunotherapy.Frontiers in immunology · 2024Review
- Reciprocal costimulatory molecules control the activation of mucosal type 3 innate lymphoid cells during engagement with B cells.Cellular & molecular immunology · 2023Article
- Chemo- and mechanosensing by dendritic cells facilitate antigen surveillance in the spleen.Immunological reviews · 2022Review
- Lymphotoxins Serve as a Novel Orchestrator in T1D Pathogenesis.Frontiers in immunology · 2022Review
- Redefining the Role of Lymphotoxin Beta Receptor in the Maintenance of Lymphoid Organs and Immune Cell Homeostasis in Adulthood.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 4 countries.
Funding
Abstract
The spleen contains a myriad of conventional dendritic cell (cDC) subsets that protect against systemic pathogen dissemination by bridging antigen detection to the induction of adaptive immunity. How cDC subsets differentiate in the splenic environment is poorly understood. Here, we report that LTα1β2-expressing Rorgt+ ILC3s, together with B cells, control the splenic cDC niche size and the terminal differentiation of Sirpα+CD4+Esam+ cDC2s, independently of the microbiota and of bone marrow pre-cDC output. Whereas the size of the splenic cDC niche depended on lymphotoxin signaling only during a restricted time frame, the homeostasis of Sirpα+CD4+Esam+ cDC2s required continuous lymphotoxin input. This latter property made Sirpα+CD4+Esam+ cDC2s uniquely susceptible to pharmacological interventions with LTβR agonists and antagonists and to ILC reconstitution strategies. Together, our findings demonstrate that LTα1β2-expressing Rorgt+ ILC3s drive splenic cDC differentiation and highlight the critical role of ILC3s as perpetual regulators of lymphoid tissue homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.